Chandarana et al., 2013 - Google Patents
Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancerChandarana et al., 2013
View HTML- Document ID
- 6354826263201012459
- Author
- Chandarana S
- Lee J
- Chanowski E
- Sacco A
- Bradford C
- Wolf G
- Prince M
- Moyer J
- Eisbruch A
- Worden F
- Giordano T
- Kumar B
- Cordell K
- Carey T
- Chepeha D
- Publication year
- Publication venue
- Head & neck
External Links
Snippet
Background The purpose of this study was to describe the relationship of p16 and epidermal growth factor receptor (EGFR) expression with survival in surgically treated patients who had oropharyngeal or oral cavity squamous cell carcinoma (SCC). Methods Tissue from 36 …
- 101700039191 EGFR 0 title abstract description 100
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chandarana et al. | Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer | |
| Maxwell et al. | Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status | |
| Li et al. | Heat shock protein 60 overexpression is associated with the progression and prognosis in gastric cancer | |
| Shi et al. | High expression of Dickkopf‐related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery | |
| Shou et al. | Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer | |
| Spector et al. | Patterns of nodal metastasis and prognosis in human papillomavirus–positive oropharyngeal squamous cell carcinoma | |
| Saad et al. | Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma | |
| Pozzan et al. | Diagnostic and prognostic role of SCCA‐IgM serum levels in hepatocellular carcinoma (HCC) | |
| Troy et al. | Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma | |
| Zhou et al. | Overexpression of PrPc, combined with MGr1‐Ag/37LRP, is predictive of poor prognosis in gastric cancer | |
| Regenbogen et al. | Elevated expression of keratin 17 in oropharyngeal squamous cell carcinoma is associated with decreased survival | |
| Pattje et al. | FADD expression is associated with regional and distant metastasis in squamous cell carcinoma of the head and neck | |
| Baumeister et al. | High expression of EpCAM and Sox2 is a positive prognosticator of clinical outcome for head and neck carcinoma | |
| Saito et al. | Prognostic value of p16 expression and alcohol consumption in Japanese patients with oropharyngeal squamous cell carcinoma | |
| Wu et al. | Novel biomarker panel predicts prognosis in human papillomavirus‐negative oropharyngeal cancer: an analysis of the TAX 324 trial | |
| Fan et al. | Expression of leptin and its receptor in thyroid carcinoma: distinctive prognostic significance in different subtypes | |
| Kim et al. | Fascin expression is related to poor survival in gastric cancer | |
| Xu et al. | Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer | |
| Pajares et al. | TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients | |
| Barasch et al. | Assessing p16 status of oropharyngeal squamous cell carcinoma by combined assessment of the number of cells stained and the confluence of p16 staining: a validation by clinical outcomes | |
| Wang et al. | Low level of Cyclin‐D1 correlates with worse prognosis of clear cell renal cell carcinoma patients | |
| Gaya et al. | ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer | |
| Feng et al. | The prognostic value of glycerol‐3‐phosphate dehydrogenase 1‐like expression in head and neck squamous cell carcinoma | |
| Tsai et al. | The correlation of cortactin and fascin‐1 expression with clinicopathological parameters in pancreatic and ampulla of Vater adenocarcinoma | |
| Yoldas et al. | Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer |